GlassScriptPhysician profile
Leah O Sanchez
NPI 1518077965
$4,192.79
in general payments reported to CMS, 2019-2025
26 companies · $28.53 in 2025
The $28.53 reported for 2025 was less than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $611 · 2020: $647 · 2021: $544 · 2022: $520 · 2023: $960 · 2024: $883 · 2025: $28.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,871.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,871.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,754.34 | 2019-2024 | Briviact, Fintepla |
| Sunovion Pharmaceuticals INC. | $683.30 | 2019-2022 | |
| Eisai INC. | $369.66 | 2019-2024 | |
| Supernus Pharmaceuticals, INC. | $249.73 | 2019-2021 | |
| Catalyst Pharmaceuticals, INC. | $249.05 | 2023-2024 | Fycompa |
| Jazz Pharmaceuticals INC. | $140.25 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $106.79 | 2023-2024 | Aptiom |
| Aquestive Therapeutics, INC. | $96.96 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $54.77 | 2024 | Nuplazid |
| Neurelis, INC. | $53.53 | 2020-2023 | Valtoco |
| Argenx US, INC. | $53.11 | 2024 | |
| Horizon Therapeutics Plc | $47.48 | 2023 | Uplizna |
| Sk Life Science, INC. | $44.92 | 2020 | |
| Amgen INC. | $29.94 | 2024 | Uplizna |
| Immedica Pharma US, INC. | $29.36 | 2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $28.53 | 2025 | Infinion 16 |
| Scilex Pharmaceuticals INC. | $27.72 | 2024 | |
| Greenwich Biosciences, INC. | $23.49 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $23.35 | 2023 | Andexxa |
| Genentech USA, INC. | $21.04 | 2024 | Ocrevus, Ocrevus Zunovo |
| Tanabe Pharma America, INC. | $20.90 | 2024 | |
| Livanova USA, INC. | $20.40 | 2020 | |
| Lundbeck LLC | $18.71 | 2024 | Vyepti |
| Aprecia Pharmaceuticals, LLC | $17.91 | 2020 | |
| Zogenix INC. | $14.78 | 2021 | |
| Upsher-Smith Laboratories LLC | $12.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leah Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.